Back to Search Start Over

[Untitled]

Authors :
James G. Miller
Glenn Davison
Christopher S. Hall
Michael J. Scott
Gregory M. Lanza
Donald H. Christy
Samuel A. Wickline
Source :
Cardiovascular Drugs and Therapy. 11:521-529
Publication Year :
1997
Publisher :
Springer Science and Business Media LLC, 1997.

Abstract

This study delineates the role of angiotensin II type I (AT1) receptor in the remodeling of Syrian cardiomyopathic hamsters. Twelve cardiomyopathic (T0-2) hamsters received L-158,809 treatment ad libitum in their drinking water (27 µg/ml) and 9 cardiomyopathic and 9 normal F1-B hamsters received tap water from 1 to 4 months of age. Although pharmacologically effective with regard to complete suppression of the blood pressure response to angiotensin II infusion, L-158,809 did not diminish the progression or severity of cardiomyopathy. Heart weight/100 g body weight and left ventricular wall thickness adjusted for body weight of both L-158,809 and cardiomyopathic control hamsters did not differ and exceeded those of F1-B controls (p < 0.05). Myocardial material properties (e.g., stiffness and density) of cardiomyopathic hamsters treated with L-158,809 were not affected. Thus, the progression of fibrosis, calcification, and necrosis in T0-2 cardiomyopathic hamsters was not sensitive to AT1 receptor blockade.

Details

ISSN :
09203206
Volume :
11
Database :
OpenAIRE
Journal :
Cardiovascular Drugs and Therapy
Accession number :
edsair.doi...........f249eba11184dad3c011990d7f055d43
Full Text :
https://doi.org/10.1023/a:1007706930979